Form 4: Zevra CCO Schafer Reports Equity Transactions

Zevra Therapeutics' Chief Commercial Officer, Joshua Schafer, reported the acquisition of new equity awards and the sale of common stock under a pre-arranged 10b5-1 plan.

Summary

• Joshua Schafer, Chief Commercial Officer (CCO) of ZEVRA THERAPEUTICS, INC., reported changes in his beneficial ownership of company securities.
• On January 29, 2026, Schafer was granted 37,500 Restricted Stock Units (RSUs) and 75,000 stock options.
• The RSUs granted on January 29, 2026, will vest as to one-third on January 29, 2027, with the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.
• The stock options granted on January 29, 2026, will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to continued service.
• On January 30, 2026, 11,333 RSUs vested and settled, converting into common stock.
• Also on January 30, 2026, Schafer sold 3,375 shares of common stock at a weighted average price of $8.8297 per share, executed under a 10b5-1 plan adopted on March 27, 2025.
• On January 31, 2026, 35,334 RSUs vested and settled, converting into common stock.
• Following these transactions, Schafer beneficially owns 37,444 shares of common stock, 37,500 new RSUs, 75,000 new stock options, 22,667 remaining RSUs from the January 30, 2026 vesting, and 35,333 remaining RSUs from the January 31, 2026 vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. The significant equity grants align the CCO's interests with long-term shareholder value, while the sale under a 10b5-1 plan is a pre-scheduled event and not indicative of negative sentiment.

Positives

• The grant of 37,500 Restricted Stock Units (RSUs) and 75,000 stock options to the CCO indicates continued alignment of management's interests with shareholders.
• The multi-year vesting schedules for the new equity awards encourage long-term retention and performance from a key executive.

Negatives

• The sale of 3,375 shares of common stock by the CCO, even under a 10b5-1 plan, represents a reduction in direct equity holdings.

Future Outlook

The vesting schedules for the newly granted Restricted Stock Units and stock options extend through January 29, 2027, and January 28, 2036, respectively, contingent on the Reporting Person's continued service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving equity grants, are common practice for executive compensation, aligning management incentives with long-term company performance. Sales under 10b5-1 plans are pre-scheduled and typically do not reflect new information about the company's prospects, distinguishing them from open market sales.

Stakeholder Impact

• Shareholders: The equity grants align management's interests with shareholders, potentially fostering long-term value creation. The sale under a 10b5-1 plan is a routine event and unlikely to have a significant direct impact.
• Employees: The equity compensation structure may serve as a model for other key personnel, potentially impacting employee retention and motivation.

Next Steps

• Continued vesting of 37,500 Restricted Stock Units, with the next tranche on January 29, 2027.
• Continued vesting of 75,000 Stock Options, with the first tranche on the first anniversary of the grant date (January 29, 2027).
• Vesting and settlement of the remaining two-thirds of the 11,333 Restricted Stock Units in equal annual installments after January 30, 2026.
• Vesting and settlement of the remaining one-third of the 35,334 Restricted Stock Units on January 31, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including equity grants and a pre-scheduled sale under a 10b5-1 plan. These events are typical for executive compensation and do not provide new fundamental information to warrant a change in investment thesis. The grants align the CCO's interests with the company's long-term performance, which is a positive, but the sale is a planned event. Therefore, a 'hold' recommendation is appropriate as there's no strong signal for buying or selling based solely on this Form 4.

Keywords

Zevra Therapeutics, ZVRA, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, CCO, Joshua Schafer, 10b5-1 Plan